Compare QTTB & SPAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QTTB | SPAI |
|---|---|---|
| Founded | 2015 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.8M | 87.0M |
| IPO Year | 2018 | N/A |
| Metric | QTTB | SPAI |
|---|---|---|
| Price | $6.12 | $3.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $13.00 | $10.00 |
| AVG Volume (30 Days) | ★ 271.5K | 225.9K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 136.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $53,737,000.00 | N/A |
| Revenue This Year | N/A | $1,060.58 |
| Revenue Next Year | N/A | $162.46 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.40 | $2.47 |
| 52 Week High | $8.05 | $9.16 |
| Indicator | QTTB | SPAI |
|---|---|---|
| Relative Strength Index (RSI) | 53.15 | 42.85 |
| Support Level | $5.51 | $3.58 |
| Resistance Level | $6.37 | $4.48 |
| Average True Range (ATR) | 0.52 | 0.39 |
| MACD | 0.07 | -0.03 |
| Stochastic Oscillator | 63.58 | 14.29 |
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
Safe Pro Group Inc operates to acquire security and protection products. Its emphasis is on the development of a cloud-based ecosystem for analyzing drone imagery and data utilizing proprietary artificial intelligence (AI), machine learning, deep learning, and applied computer vision software for hyper-scalable processing, analysis, and reporting. The company operated in three reportable business segments which consisted of: the business of Safe-Pro USA, the business of Airborne Response, and the business of Safe Pro AI. Key revenue is generated from Airborne Response.